Geodon for the Treatment of Refractory Social Anxiety Disorder (SAD)
Social Anxiety Disorder
About this trial
This is an interventional treatment trial for Social Anxiety Disorder focused on measuring anxiety disorder, SAD, ziprasidone, sertraline, antidepressant, antipsychotic
Eligibility Criteria
Inclusion Criteria: adults 18-65 years of age primary diagnosis of SAD, using Diagnostic Standard Manual(DSM-IV) criteria minimum Clinical Global Impression of Severity (CGI-S) score of 4 at baseline minimum Brief Social Phobia Scale(BSPS) score of 20 at baseline written informed consent negative serum pregnancy test for women of childbearing potential normal EKG Exclusion Criteria: current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition any current primary anxiety disorder other than SAD current primary depression history of substance abuse or dependence within the last 3 months suicide risk or serious suicide attempt within the last year clinically significant medical condition or laboratory or EKG abnormality women of childbearing potential who are unwilling to practice an acceptable method of contraception patients needing concurrent use of psychotropic medications history of hypersensitivity to sertraline or ziprasidone recent (less than 2 months) initiation of psychotherapy for SAD history of failure to respond to augmentation with an adequate trial of an atypical antipsychotic patients who are currently taking any of the following medications: Erythromycin, Biaxin, Avelox, Zithromax, Amantadine, Levaquin, Tamoxifen, Tegretol, Nizoral, and Levitra
Sites / Locations
- Duke University Medical Center
- Duke University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Other
Open Label Treatment
Randomization Ziprasidone
Randomization Placebo
8 weeks of open label treatment with sertraline
8 weeks of treatment with sertraline augmented with ziprasidone
8 weeks of treatment with sertraline augmented by placebo